Thalidomide affects the skeletal system of ovariectomized rats

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pharmacological Reports

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1734-1140(09)70096-9PMID 19605953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Thalidomide embryopathy].

  2020cited by this paper
• Estrogens and Progestins

  2010cited by this paper
• Estrogens and Progestins

  2008cited by this paper
• Mechanisms of Estrogen Action in Bone

  2008cited by this paper
• The thalidomide saga.

  2007cited by this paper
• Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats.

  2007cited by this paper
• Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies

  2007influential reference
• Thalidomide and its dermatologic uses.

  2007cited by this paper
• Raloxifene similarly affects the skeletal system of male and ovariectomized female rats.

  2007cited by this paper
• The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

  2007cited by this paper
• Thalidomide in the treatment of multiple myeloma.

  2007cited by this paper
• Effects of thalidomide in experimental models of post‐endoscopic retrograde cholangiopancreatography pancreatitis

  2007cited by this paper
• Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation.

  2006cited by this paper
• Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease

  2006cited by this paper
• Scleromyxedema: Successful Treatment with Thalidomide in Two Patients

  2006cited by this paper
• First‐line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

  2006cited by this paper
• Effect of adminitration of etidronate and retinol on bone mechanical properties in ovariectomized rats.

  2005cited by this paper
• Tetracycline-based histological analysis of bone remodeling

  2005cited by this paper
• Thalidomide in the management of epidermolysis bullosa pruriginosa

  2005cited by this paper
• Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

  2005cited by this paper
• Myeloma bone disease: pathophysiology and management.

  2005cited by this paper
• Thalidomide: dermatological indications, mechanisms of action and side‐effects

  2005cited by this paper
• The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

  2005cited by this paper
• Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

  2004cited by this paper
• Effect of administration of retinol and etidronate on bone histomorphometric parameters in ovariectomized rats.

  2004cited by this paper
• New cytokine therapeutics for inflammatory bowel disease.

  2004influential reference
• Effects of Doxycycline on Mechanical Properties of Bones in Rats with Ovariectomy-Induced Osteopenia

  2004cited by this paper
• Thalidomide for the treatment of multiple myeloma.

  2003cited by this paper
• Ovariectomy and estrogen replacement in rodents.

  2003cited by this paper
• Thalidomide blocking of particle-induced TNFalpha release in vitro.

  2003cited by this paper
• Dermatologic and Nondermatologic Uses of Thalidomide

  2003cited by this paper
• Thalidomide blocking of particle-induced TNFα release in vitro

  2003cited by this paper
• Thalidomide metabolism by the CYP2C subfamily.

  2002cited by this paper
• Thalidomide as an anti‐cancer agent

  2002cited by this paper
• Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells

  2002cited by this paper
• Thalidomide and Its Dermatologic Uses

  2001cited by this paper
• Clinical pharmacology of thalidomide

  2001cited by this paper
• Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.

  1998cited by this paper
• Complete Drug Reference

  1996cited by this paper
• Goodman and Gilman 's: The pharmacological basis of therapeutics

  1996cited by this paper
• New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130.

  1995cited by this paper
• Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.

  1995influential reference
• Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis

  1995cited by this paper
• Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period.

  1995cited by this paper
• On the rat model of human osteopenias and osteoporoses.

  1992cited by this paper
• Estrogen and diphosphonate treatment provide long‐term protection against osteopenia in ovariectomized rats

  1991cited by this paper
• Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

  1991cited by this paper
• The ovariectomized rat model of postmenopausal bone loss.

  1991cited by this paper
• Mechanisms of estrogen action on bone.

  1989cited by this paper
• Mechanisms of estrogen action on bone.

  1989cited by this paper
• Characteristics of an ovariectomized osteopenic rat model

  1989cited by this paper
• Congenital short femur. Clinical, genetic and epidemiological comparison of the naturally occurring condition with that caused by thalidomide.

  1980cited by this paper
• Thalidomide embryopathy.

  1977cited by this paper

• E3 Ubiquitin Ligases: Potential Therapeutic Targets for Skeletal Pathology and Degeneration

  2022cites this paper
• Antiosteopenic Effect of Buffalo Milk Casein-Derived Peptide (NAVPITPTL) in Ovariectomized Rats

  2018cites this paper
• Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats.

  2017cites this paper
• Thymoquinone Attenuates Ovariectomy Induced Alteration in Bone Architecture and Metabolism in Rats

  2015cites this paper
• A phenome-guided drug repositioning through a latent variable model

  2014cites this paper
• The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model

  2014cites this paper
• Thalidomide affects the skeletal system of young rats.

  2013cites this paper
• Effect of Formononetin on Mechanical Properties and Chemical Composition of Bones in Rats with Ovariectomy-Induced Osteoporosis

  2013cites this paper
• Thymoquinone Treatment Alleviate Ovariectomy-Induced Hepatic Oxidative Damage in Rats

  2013cites this paper
• Effects of thalidomide on the development of bone damage caused by prednisolone in rats.

  2012influential citation
• Effects of thalidomide on the development of bone damage caused by prednisolone in rats

  2012cites this paper
• Effects of curcumin on the skeletal system in rats

  2010cites this paper